Table 2 Baseline characteristics of the patients recruited for the study. Data are expressed as mean ± standard deviation (SD) or percentages (%). Statistical differences between groups of patients were calculated by one-way ANOVA (p < 0.05 was considered significantly).
Discovery phase | Control (n = 10) | CV risk factor (n = 8) | CV event (n = 8) | P-value |
|---|---|---|---|---|
Age (years) | 44 ± 5 | 44 ± 6 | 46 ± 4 | 0.700 |
Sex (male), % | 60 | 50 | 50 | 0.884 |
Current smoking, % | 0 | 25 | 50 | 0.043 |
Total cholesterol (mg/dl) | 187 ± 25 | 206 ± 39 | 145 ± 40 | 0.008 |
HDL cholesterol (mg/dl) | 72 ± 18 | 53 ± 13 | 44 ± 10 | 0.001 |
LDL cholesterol (mg/dl) | 101 ± 24 | 131 ± 36 | 77 ± 32 | 0.010 |
Triglycerides (mg/dl) | 73 ± 26 | 139 ± 130 | 124 ± 67 | 0.222 |
Glycaemia (mg/dl) | 76 ± 7 | 104 ± 48 | 94 ± 30 | 0.280 |
Uric acid (mg/dl) | 4.8 ± 1.6 | 5 ± 1 | 5.5 ± 1.6 | 0.620 |
Metabolic syndrome, % | 0 | 25 | 38 | 0.171 |
eGFR (ml/min/1.73 m2) | 91 ± 9 | 97 ± 22 | 103 ± 34 | 0.585 |
Systolic blood pressure (mmHg) | 113 ± 10 | 131 ± 5 | 125 ± 19 | 0.017 |
Diastolic blood pressure (mmHg) | 72 ± 8 | 84 ± 10 | 78 ± 9 | 0.034 |
Antihypertensives, % | 0 | 25 | 13 | 0.354 |
Lipid-lowering agents, % | 0 | 13 | 13 | 0.622 |
QRISK | 22 ± 5 | 33 ± 9 | 27 ± 6 | 0.004 |
Confirmation phase | Control (n = 14) | CV risk factor (n = 15) | CV event (n = 16) | P-value |
Age (years) | 42 ± 5 | 45 ± 5 | 45 ± 5 | 0.131 |
Sex (male), % | 21 | 80 | 94 | 6.20E-05 |
Current smoking, % | 21 | 27 | 56 | 0.094 |
Total cholesterol (mg/dl) | 198 ± 47 | 215 ± 39 | 145 ± 41 | 0.0001 |
HDL cholesterol (mg/dl) | 69 ± 18 | 41 ± 16 | 39 ± 9 | 1.18E-06 |
LDL cholesterol (mg/dl) | 109 ± 40 | 139 ± 34 | 82 ± 40 | 6.90E-04 |
Triglycerides (mg/dl) | 92 ± 46 | 221 ± 80 | 113 ± 67 | 5.18E-06 |
Glycaemia (mg/dl) | 80 ± 9 | 95 ± 22 | 100 ± 15 | 3.90E-03 |
Uric acid (mg/dl) | 4.5 ± 1.1 | 6.7 ± 1.8 | 5.8 ± 1.7 | 1.99E-03 |
Metabolic syndrome, % | 0 | 73 | 6 | 1.77E-13 |
eGFR (ml/min/1.73 m2) | 95 ± 12 | 83 ± 9 | 94 ± 17 | 0.032 |
Systolic blood pressure (mmHg) | 112 ± 9 | 138 ± 14 | 121 ± 20 | 1.30E-04 |
Diastolic blood pressure (mmHg) | 70 ± 9 | 90 ± 9 | 76 ± 12 | 1.76E-06 |
Antihypertensives, % | 0 | 40 | 44 | 0.016 |
Lipid-lowering agents, % | 0 | 27 | 38 | 0.042 |
QRISK | 23 ± 9 | 44 ± 9 | 36 ± 10 | 1.38E-06 |
